Why some targeted cancer therapies eventually fail

Therapies tailored to the genetics of a particular tumor type are helping lung cancer patients live longer, but cancer usually returns. When it comes back, the cancer is better than ever at surviving therapy. A new paper from Associate Professor Raffaella Sordella reveals a way that non-genetic changes in cancer cells lead to genetic changes that increase resistance to targeted therapies. Read more.